- The FDA has decided not to authorize Cariprazine, a treatment for schizophrenia and bipolar disorder that Forest Labs (FRX) has licensed from Hungarian firm Gedeon Richter (GEDRY).
- In a complete response letter, the FDA said Cariprazine demonstrated effectiveness, although it seems that the regulator wants more tests carried out on the optimal dose of the drug in order to avoid potential side effects.
- Richter said it would be able to ascertain for certain whether more tests are needed following consultations with the FDA.
- Analysts had forecast sales of $250M by 2017 if the treatment were to be approved. (PR)
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at MarketWatch.com (Jul 1, 2014)
at CNBC.com (Jul 1, 2014)
at CNBC.com (Jun 24, 2014)
at CNBC.com (Jun 17, 2014)
at CNBC.com (May 27, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs